How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Information about lorlatinib

    Marketing authorisation indication

    2.1 Lorlatinib (Lorviqua, Pfizer) as monotherapy is indicated for 'the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after:

    • alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or

    • crizotinib and at least one other ALK TKI'.

    Dosage in the marketing authorisation

    2.2 The recommended dose is 100 mg lorlatinib taken orally once daily. Treatment with lorlatinib is recommended as long as the patient is benefitting from therapy without unacceptable toxicity.

    Price

    2.3 The list price of lorlatinib is £7,044.00 per 120-tablet pack of 25 mg tablets, and £5,283.00 per 30-tablet pack of 100 mg tablets (excluding VAT; BNF online accessed January 2020). The company has a commercial arrangement, which would have applied if the technology had been recommended.